Treatment of atypical uraemic syndrome in the era of eculizumab

about

Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab.A curious case of haemolysis, seizure and acute renal failure associated with pregnancy.Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?

P2860

Q33403172-EB817AC2-9A3D-4964-AB81-7FFE47C1F0C6 Q33413064-DB2B3106-8483-4ADF-A68B-66D286FCDBB5 Q42000134-5144C0D7-1E4D-416F-B4AE-03850810CC34

P2860

Treatment of atypical uraemic syndrome in the era of eculizumab

Item

http://www.wikidata.org/entity/Q39719068

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Treatment of atypical uraemic syndrome in the era of eculizumab

@en

Treatment of atypical uraemic syndrome in the era of eculizumab.

@nl

type

Item

label

Treatment of atypical uraemic syndrome in the era of eculizumab

@en

Treatment of atypical uraemic syndrome in the era of eculizumab.

@nl

prefLabel

Treatment of atypical uraemic syndrome in the era of eculizumab

@en

Treatment of atypical uraemic syndrome in the era of eculizumab.

@nl

P1476

Treatment of atypical uraemic syndrome in the era of eculizumab

@en

P2093

Veronique Fremeaux-Bacchi

http://www.w3.org/2001/XMLSchema#string

P2860

Atypical hemolytic uremic syndrome

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

The development of atypical hemolytic uremic syndrome depends on complement C5

Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.

Atypical hemolytic-uremic syndrome.

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.

P304

4-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1093/CKJ/SFR177

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Véronique Frémeaux-Bacchi

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273557656

http://www.w3.org/2001/XMLSchema#string

P698

26069738

http://www.w3.org/2001/XMLSchema#string

P932

4400466

http://www.w3.org/2001/XMLSchema#string

Treatment of atypical uraemic syndrome in the era of eculizumab

about

P2860

P2860

Treatment of atypical uraemic syndrome in the era of eculizumab

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932